
After a busy year marked by major commercial milestones for Antheia, we are excited to announce $56 million in Series C financing. With the support of new and existing investors, we are entering a new chapter as a business, bringing us closer than ever to a world without essential medicine shortages.
With this new investment, we will ramp up our commercial production of thebaine, a key starting material for Narcan – an essential medicine for reversing opioid overdoses – and launch new products from our pipeline to meet our growing customer demand. The funds will also support the development of Antheia’s U.S. manufacturing operations and unlock opportunities in strategic new areas like drug discovery and innovation.
At a recent event hosted by the National Security Commission on Emerging Biotechnology, CEO and co-founder, Dr. Christina Smolke said, “We have the most creative and independent workforce in the U.S. that enables what’s considered impossible to become possible – we allow our scientists to dream and we push them to do things no one else in the world can do.” Nowhere is this more true than at Antheia.
The brilliant team at Antheia is responsible for the industry-first achievements we’ve reached and the success we’ve realized. Every department and individual has played a crucial role in this effort, from R&D and manufacturing to finance and operations. We simply could not do it without each person’s dedication, passion, and focus. The Antheia team has made what was once deemed impossible – engineering yeast cells with complex biosynthesis pathways comprising 40-50 enzymes – not only possible, but commercially viable and scalable.
While there is much work ahead of us, we’d like to take this moment to pause, reflect, and feel proud of all we have already accomplished together. What we started in a lab at Stanford in 2008 has now grown into a commercial biomanufacturing company producing some of the most in-demand pharmaceutical ingredients in the industry. We are providing our customers with the high-quality ingredients they need to produce life-saving treatments in a fraction of the time it would typically take with legacy, agricultural sourcing. And as we grow, we are advancing our mission to make efficient, resilient, and sustainable global pharma supply chains a reality.
We look forward to everything this next chapter has in store for us, and are grateful to our Antheia colleagues for their contributions in making the impossible possible.
Follow Antheia on LinkedIn and X/Twitter.